Mechanistically, EHMT2 promoted activation of WNT/β-catenin signaling in T-SCLC cell lines through epigenetic silencing of SFRP1, a negative regulator of the WNT/β-catenin pathway [48]. This evidence concerns the gene EHMT2 and small cell lung carcinoma.